(Q34288123)

1 August 2017

1 reference

title

Cytokines in cancer pathogenesis and cancer therapy (English)

1 reference

1 August 2017

0 references

Glenn Dranoff

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

1 August 2017

published in

Nature Reviews Cancer

1 reference

1 August 2017

volume

4

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

11-22

1 reference

1 August 2017

cites work

The Hallmarks of Cancer

1 reference

The microenvironment of the tumour-host interface

31 March 2020

1 reference

Angiogenesis in cancer, vascular, rheumatoid and other disease

31 March 2020

1 reference

Model predicting survival in stage I melanoma based on tumor progression

31 March 2020

1 reference

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

31 March 2020

1 reference

Cancer immunoediting: from immunosurveillance to tumor escape

31 March 2020

1 reference

The causes and prevention of cancer

31 March 2020

1 reference

31 March 2020

Inflammation and cancer

1 reference

Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

31 March 2020

1 reference

Pleiotropy and redundancy: T cell-derived lymphokines in the immune response

31 March 2020

1 reference

How the immune system works to protect the host from infection: a personal view

31 March 2020

1 reference

On natural and artificial vaccinations

31 March 2020

1 reference

The innate immune response to tumors and its role in the induction of T-cell immunity

31 March 2020

1 reference

NK cells, MHC class I molecules and the missing self

31 March 2020

1 reference

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

31 March 2020

1 reference

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

31 March 2020

1 reference

31 March 2020

The B7-CD28 superfamily

1 reference

Dendritic cells and the control of immunity

31 March 2020

1 reference

Human tumor antigens recognized by T lymphocytes

31 March 2020

1 reference

New paths in human cancer serology

31 March 2020

1 reference

Human neoplasms elicit multiple specific immune responses in the autologous host

31 March 2020

1 reference

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

31 March 2020

1 reference

Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

31 March 2020

1 reference

Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction

31 March 2020

1 reference

The IFN gamma receptor: a paradigm for cytokine receptor signaling

31 March 2020

1 reference

Differential tumor surveillance by natural killer (NK) and NKT cells.

31 March 2020

1 reference

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

31 March 2020

1 reference

Regulation of cutaneous malignancy by gammadelta T cells

31 March 2020

1 reference

Resident skin-specific gammadelta T cells provide local, nonredundant regulation of cutaneous inflammation

31 March 2020

1 reference

Gamma delta T cells provide an early source of interferon gamma in tumor immunity

31 March 2020

1 reference

Decreased tumor surveillance in perforin-deficient mice

31 March 2020

1 reference

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

31 March 2020

1 reference

Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma

31 March 2020

1 reference

Suppression of lymphoma and epithelial malignancies effected by interferon gamma

31 March 2020

1 reference

Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions

31 March 2020

1 reference

The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity

31 March 2020

1 reference

Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer

31 March 2020

1 reference

Infections as a major preventable cause of human cancer

31 March 2020

1 reference

Interleukin-1 polymorphisms associated with increased risk of gastric cancer

31 March 2020

1 reference

Immune pathogenesis of hepatocellular carcinoma.

31 March 2020

1 reference

Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy

31 March 2020

1 reference

Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells

31 March 2020

1 reference

Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.

31 March 2020

1 reference

A proinflammatory cytokine inhibits p53 tumor suppressor activity

31 March 2020

1 reference

Interleukin 6 is essential for in vivo development of B lineage neoplasms

31 March 2020

1 reference

Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy

31 March 2020

1 reference

IL-1 is required for tumor invasiveness and angiogenesis

31 March 2020

1 reference

MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis

31 March 2020

1 reference

Involvement of chemokine receptors in breast cancer metastasis

31 March 2020

1 reference

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

31 March 2020

1 reference

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

31 March 2020

1 reference

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

31 March 2020

1 reference

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

31 March 2020

1 reference

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

31 March 2020

1 reference

Interleukin 2 signaling is required for CD4(+) regulatory T cell function

31 March 2020

1 reference

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

31 March 2020

1 reference

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

31 March 2020

1 reference

Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer

31 March 2020

1 reference

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

31 March 2020

1 reference

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group

31 March 2020

1 reference

Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy

31 March 2020

1 reference

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

31 March 2020

1 reference

Antitumor Efficacy of Adenocarcinoma Cells Engineered to Produce Interleukin 12 (IL-12) or Other Cytokines Compared With Exogenous IL-12

31 March 2020

1 reference

Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.

31 March 2020

1 reference

CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion

31 March 2020

1 reference

The central role of CD4(+) T cells in the antitumor immune response

31 March 2020

1 reference

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas

31 March 2020

1 reference

Cytokine-secreting tumor cell vaccines

31 March 2020

1 reference

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

31 March 2020

1 reference

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction

31 March 2020

1 reference

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction

31 March 2020

1 reference

Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy

31 March 2020

1 reference

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma

31 March 2020

1 reference

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

31 March 2020

1 reference

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

31 March 2020

1 reference

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

31 March 2020

1 reference

Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells

31 March 2020

1 reference

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

31 March 2020

1 reference

Control of T-cell activation by CD4+ CD25+ suppressor T cells

31 March 2020

1 reference

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

31 March 2020

1 reference

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

31 March 2020

1 reference

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

31 March 2020

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

31 March 2020

1 reference

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

31 March 2020

1 reference

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

31 March 2020

1 reference

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

31 March 2020

1 reference

Two upstream elements activate transcription of a major histocompatibility complex class I genein vitro

31 March 2020

1 reference

Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene

31 March 2020

1 reference

Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder

31 March 2020

1 reference

ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells

31 March 2020

1 reference

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

31 March 2020

1 reference

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

31 March 2020

1 reference

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

31 March 2020

1 reference

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

31 March 2020

1 reference

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

31 March 2020

1 reference

Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells

31 March 2020

1 reference

An eosinophil-dependent mechanism for the antitumor effect of interleukin-4

31 March 2020

1 reference

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

31 March 2020

1 reference

Interleukin 7 induces CD4+ T cell-dependent tumor rejection

31 March 2020

1 reference

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

31 March 2020

1 reference

NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway

31 March 2020

1 reference

Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo

31 March 2020

1 reference

Interferons alpha and beta as immune regulators--a new look

31 March 2020

1 reference

Tumor necrosis factor: a pleiotropic cytokine and therapeutic target

31 March 2020

1 reference

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

31 March 2020

1 reference

Flt3 ligand induces tumor regression and antitumor immune responses in vivo

31 March 2020

1 reference

Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma

31 March 2020

1 reference

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC1252

1 reference

Dimensions Publication ID

1 August 2017

1037065448

0 references

1 reference